New Spleen Tyrosine Kinase Inhibitors: Patent Applications Published During 2011–2013

Atli Thorarensen · Neelu Kaila

8 citations0/0 files storedPharmaceutical Patent Analyst

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Intellectual Property and Patents Computational Drug Discovery Methods Protein Kinase Regulation and GTPase Signaling

Abstract

Spleen tyrosine kinase (SYK) is one of the more advanced small-molecule targets with regard to clinical development for treatment of inflammatory diseases. In this review we continue our analysis of the patent literature covering the time period 2011-2013. The analysis relates to any organization that has filed applications that explicitly discloses SYK as the intended target. In the last 2 years there has been a surge of application with a few new entries in a crowded field with the structural theme of compounds in these applications being a traditional type I ATP competitive inhibitor [ 1 ]. This overview of the SYK patent literature and the learning's of the inhibitors substitution patterns would be an important reading for anyone working in the area of SYK inhibitors.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 8 citations exist upstream.

References

2013Forensic expertise at Congress 2010An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola 2012The 2010 Patent Landscape for Spleen Tyrosine Kinase Inhibitors+

Imported from OpenAlex (CC0) — nothing here is generated.